Skip to main content

Generate Biomedicines, Inc 10-Q for FY2026 Q3

Generate Biomedicines, Inc. (GENB)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Generate Biomedicines, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$4.22M
down 56.2% from $9.63M a year earlier
Net loss
$87.66M
compared with a net loss of $53.62M a year earlier
Diluted EPS
-$0.68
compared with -$1.97 a year earlier